Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    NCT01312012
Previous Study | Return to List | Next Study

The Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01312012
First received: January 20, 2011
Last updated: April 11, 2014
Last verified: April 2014

January 20, 2011
April 11, 2014
January 2011
December 2013   (final data collection date for primary outcome measure)
child-HBsAg [ Time Frame: 6 months after delivery ] [ Designated as safety issue: No ]
serum status of HBsAg of the infants at 6 months old( >180 days).
Same as current
Complete list of historical versions of study NCT01312012 on ClinicalTrials.gov Archive Site
1. child HBsAg; 2.maternal viral load, HBeAg, and ALT [ Time Frame: 1. 12 months after delivery (infant); 2. 8 weeks after taking medication (mothers) ] [ Designated as safety issue: No ]
  1. Serum status of HBsAg of the infants at 12 months old, to see whether this child indeed becomes a chronic carrier of HBV.
  2. The change of maternal viral load, HBeAg, and liver function, at 8 weeks after medication.
Same as current
Not Provided
Not Provided
 
The Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test
The Effectiveness and Feasibility of Using Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test

Since the implementation of universal vaccination in 1984, the chronic HBV carier rate in our general population reduced from 15-20%, down to < 1% in the post-vaccination population. However, children born to HBeAg positive mothers still may be infected with HBV despite immunization. To further reducing the HBV infection in our people, strategies in reducing infection rate in this high risk group are mandatory. Previous small scale studies using lamivudine treatment in pregnant woman in the third trimester has proved effective in reducing children infection rate. The aims of the present study are to conduct a clinical trial in using Tenofovir (category B) to reduce mother-to-infant transmission, and to monitor the hepaitits B viral status and mother hepatitis occurrence. This is a 3.5 year study. The clinical trials will screen 300 cases of HBsAg positive pregnant women aged 20 to 40 years at gestational at 20-32 weeks. They will be tested for HBsAg and HBeAg. In whom both markers are positive, HBV viral load will be tested. An estimated 100~120 pregnant women with high HBV viral load (>10^8 copies/mL) will be recruited in the study; including 65-55 subjects treated with Tenofovir 300 mg daily starting from 30-32 weeks of gestation (3rd trimester) and continued to 1 month after delivery; and 45-55 pregnant women are enrolled as controls with no drug given to the mother. The newborn babies are given with HBIG within 24 hours after delivery, and HBV vaccines at 0, 1 and 6 months. Maternal complete blood count (CBC) data tested in the first prenatal examination will be recorded. Plasma AST、ALT levels and HBV DNA are tested before Tenofovir treatment, 1 month after treatment, at the time of delivery, and at 1, 2, 4 and 6 months after delivery. HBsAg、HBeAg、anti-HBs and AST、ALT are tested in the children at day 1, 6 moths and 1 year after birth. The primary outcome is reduction of the HBsAg carrier rate of the children at 6 months of age. The secondary outcome is HBsAg carrier rate of the children at 12 months of age, the change of liver function, HBeAg, and viral load in pregnant mother 8 weeks after treatment. The results of the present study will provide potentially applicable methods for reducing mother-to-infant HBV transmission.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Hepatitis B Virus Infection, Pregnancy
Drug: antiviral therapy
100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level > 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
  • Experimental: The effectiveness and feasibility, using antiviral therapy
    Experimental: Subjects receive tenofovir disoproxil fumarate (TDF) oral use prior to delivery in pregnant women with positive serum HBeAg and HBsAg and high HBV DNA levels > 10^8copies / mL, to reduce the rate of mother to infant transmission of HBV infection, and also to monitor the safety of the therapy.
    Intervention: Drug: antiviral therapy
  • No Intervention: Control
    Subjects receive no intervention, but with blood tests for mothers and infants before and after delivery, as a comparative group to experimental arm.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
120
December 2014
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

- pregnant women in 30 to 32 weeks of gestation, with positive HBsAg and HBeAg,serum viral load above 8log10 copies per mL

Exclusion Criteria:

  • major systemic disease
  • Pregnant woman with infection of human immunodeficiency virus or hepatitis C virus
  • Pregnant woman is receiving any drug with antiviral activity or any form of drug therapy for hepatitis B virus
  • Pregnant woman whose ultrasonographic examination reveals congenital anomaly of the fetus
  • Pregnant woman whose amniocentesis reveals any genetic abnormality
Female
20 Years to 40 Years
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT01312012
201010078M
No
National Taiwan University Hospital
National Taiwan University Hospital
Not Provided
Principal Investigator: Mei-Hwei Chang, PhD National Taiwan University
National Taiwan University Hospital
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP